These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 9589263)
1. Cannula occlusion with use of insulin lispro and insulin infusion system. Wright AW; Little JA Diabetes Care; 1998 May; 21(5):874-5. PubMed ID: 9589263 [No Abstract] [Full Text] [Related]
5. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Attia N; Jones TW; Holcombe J; Tamborlane WV Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247 [TBL] [Abstract][Full Text] [Related]
6. A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications? Ampudia-Blasco FJ; Hasbum B; Carmena R Diabetes Care; 2003 Mar; 26(3):953-4. PubMed ID: 12610070 [No Abstract] [Full Text] [Related]
7. Insulin lispro: the ideal pump insulin for patients with severe hypoglycemic unawareness? Ooi C; Mullen P; Williams G Diabetes Care; 1999 Sep; 22(9):1598-9. PubMed ID: 10480541 [No Abstract] [Full Text] [Related]
9. Insulin lispro--a review. Muzaffer Z; Iqbal A; Ristic S J Pak Med Assoc; 1998 Jul; 48(7):212-4. PubMed ID: 10067027 [No Abstract] [Full Text] [Related]
10. Designer insulins: moving closer to convenient and physiological replacement of insulin. Boyages SC Med J Aust; 1999 Apr; 170(8):349-50. PubMed ID: 10327943 [No Abstract] [Full Text] [Related]
11. [Pharmaceutical development and clinical experiment of new antidiabetic drugs, premixed preparations of insulin lispro (Humalog Mix 25 and Humalog Mix 50) and intermediate-acting insulin lispro (Humalog N)]. Awa T; Nakata T; Shigeta H Nihon Yakurigaku Zasshi; 2005 Aug; 126(2):143-51. PubMed ID: 16205018 [No Abstract] [Full Text] [Related]
12. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. DeFelippis MR; Bell MA; Heyob JA; Storms SM Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment with insulin analog lispro in IDDM with delayed absorption of subcutaneously applied human regular insulin and complicated intraperitoneal insulin infusion. A case report. Meier M; Brand J; Standl E; Schnell O Diabetes Care; 1998 Jul; 21(7):1044-5. PubMed ID: 9653592 [TBL] [Abstract][Full Text] [Related]
14. Vitiligo associated with subcutaneous insulin lispro infusion in type 1 diabetes. Burge MR; Carey JD Diabetes Care; 2004 Jan; 27(1):275-6. PubMed ID: 14694005 [No Abstract] [Full Text] [Related]
15. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause? Griffin ME; Feder A; Tamborlane WV Diabetes Care; 2001 Jan; 24(1):174. PubMed ID: 11194227 [No Abstract] [Full Text] [Related]
16. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes. Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683 [No Abstract] [Full Text] [Related]
18. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients. Rave K; Heinemann L; Puhl L; Gudat U; Woodworth JR; Weyer C; Heise T Diabetes Care; 1999 May; 22(5):865-6. PubMed ID: 10332707 [No Abstract] [Full Text] [Related]
19. Insulin confusion: an observation. Phillips W; Lando H Diabetes Care; 2002 Jun; 25(6):1103-4. PubMed ID: 12032129 [No Abstract] [Full Text] [Related]
20. New developments in the treatment of type 1 diabetes in children. Danne T; Lange K; Kordonouri O Arch Dis Child; 2007 Nov; 92(11):1015-9. PubMed ID: 17954479 [No Abstract] [Full Text] [Related] [Next] [New Search]